Editorial: A target or a demi-target

Clinical Lung Cancer

Volumn 11, Issue 3, 2010, Pages 147-148

  Mok, Tony S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; ANTINEOPLASTIC AGENT; TUMOR MARKER;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESEARCH; CHROMOSOME 2; CHROMOSOME 4; DRUG TARGETING; EDITORIAL; EXON; FUSION GENE; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; LUNG CANCER; ONCOGENE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; TREATMENT RESPONSE; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; METHODOLOGY; MOLECULAR BIOLOGY; NEOPLASM; STANDARD;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 77952511618     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2010.n.018     Document Type: Editorial

References (11)

1. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumor. Gastroenterology 2003; 125:660-667
2. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumor. N Engl J Med 2002; 347:472-480
3. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361:947-957
4. Kobayashi K, Inoue A, Maemondo M, et al. First-line gefitinib versus first-line chemotherapy by carboplatin (CBDCA) plus paclitaxel (TXL) in non-small cell lung cancer (NSCLC) patients (pts) with EGFR mutations: a phase III study (002) by North East Japan Gefitinib Study Group. J Clin Oncol 2009; 27(15 suppl): (abstract 8016).
5. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 2010; 11:121-128
6. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009; 27:4247-4253
7. Kwak EL, Camidge DR, Clark JW Clinical activity observed in a phase 1 dose escalation trial of an oral C-MET and ALK inhibitor, PF-02341066. J Clin Oncol 2009; 27(15 suppl): (abstract 3509).
8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676
9. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355:2542-2550
10. Reck M, Von Pawel J, Zatloukal P et al. Phase III trial of cisplatin plus gem- citabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27:1227-1234
11. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. Lancet 2009; 373:1525-1531